Lifecore Biomedical Stock Price To Earnings To Growth
LFCR Stock | 7.41 0.42 6.01% |
Fundamental analysis of Lifecore Biomedical allows traders to better anticipate movements in Lifecore Biomedical's stock price by examining its financial health and performance throughout various phases of its business cycle.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Lifecore Biomedical Company Price To Earnings To Growth Analysis
Lifecore Biomedical's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Lifecore Biomedical Price To Earnings To Growth | 3.51 X |
Most of Lifecore Biomedical's fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
Competition |
Based on the latest financial disclosure, Lifecore Biomedical has a Price To Earnings To Growth of 3.513 times. This is 394.79% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The price to earnings to growth for all United States stocks is 28.16% higher than that of the company.
Did you try this?
Run Equity Forecasting Now
Equity ForecastingUse basic forecasting models to generate price predictions and determine price momentum |
All Next | Launch Module |
Lifecore Fundamentals
Return On Equity | -0.84 | ||||
Return On Asset | -0.0311 | ||||
Profit Margin | (0.34) % | ||||
Operating Margin | (0.07) % | ||||
Current Valuation | 383.36 M | ||||
Shares Outstanding | 37.03 M | ||||
Shares Owned By Insiders | 2.06 % | ||||
Shares Owned By Institutions | 72.43 % | ||||
Number Of Shares Shorted | 2.45 M | ||||
Price To Book | 115.94 X | ||||
Price To Sales | 1.99 X | ||||
Revenue | 128.26 M | ||||
Gross Profit | 43.59 M | ||||
EBITDA | 35.6 M | ||||
Net Income | 9.33 M | ||||
Total Debt | 130.36 M | ||||
Book Value Per Share | 0.06 X | ||||
Cash Flow From Operations | (217 K) | ||||
Short Ratio | 10.48 X | ||||
Earnings Per Share | (1.47) X | ||||
Price To Earnings To Growth | 3.51 X | ||||
Target Price | 10.0 | ||||
Number Of Employees | 524 | ||||
Beta | 0.71 | ||||
Market Capitalization | 259.18 M | ||||
Total Asset | 273.7 M | ||||
Retained Earnings | (166.52 M) | ||||
Working Capital | 42.16 M | ||||
Net Asset | 273.7 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lifecore Biomedical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lifecore Biomedical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lifecore Biomedical will appreciate offsetting losses from the drop in the long position's value.Moving against Lifecore Stock
0.69 | ACB | Aurora Cannabis Earnings Call Today | PairCorr |
0.56 | CGC | Canopy Growth Corp Earnings Call This Week | PairCorr |
0.55 | ETON | Eton Pharmaceuticals Earnings Call This Week | PairCorr |
0.53 | HLN | Haleon plc | PairCorr |
0.51 | BGM | Qilian International Symbol Change | PairCorr |
The ability to find closely correlated positions to Lifecore Biomedical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lifecore Biomedical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lifecore Biomedical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lifecore Biomedical to buy it.
The correlation of Lifecore Biomedical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lifecore Biomedical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lifecore Biomedical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lifecore Biomedical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.